[시장보고서]항진균제 시장 보고서 : 약제 클래스별, 적응증별, 지역별(2025-2033년)

항진균제 시장 보고서 : 약제 클래스별, 적응증별, 지역별(2025-2033년)

Antifungal Drugs Market Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, and Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), and Region 2025-2033

상품코드 : 1820200

리서치사 : IMARC

발행일 : 2025년 09월

페이지 정보 : 영문 146 Pages

라이선스 & 가격 (부가세 별도)

US $ 2,999

￦ 4,359,000

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트 등의 Copy&Paste도 불가능합니다.

US $ 3,999

￦ 5,813,000

PDF & Excel (5 User License)

PDF & Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 불가능합니다. 인쇄는 5부까지 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,999

￦ 7,267,000

PDF & Excel (Corporate License)

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계 항진균제 시장 규모는 2024년 156억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 206억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 2.99%를 보일 것으로 예측했습니다. 곰팡이 감염증의 유병률 증가, 항진균제 시장 개척의 진전, 진단 기술의 향상, 노인 인구 증가 등이 시장 성장을 주도하고 있습니다.

항진균제 시장 동향 :

곰팡이 감염 유병률 증가

칸디다증, 아스페르길루스증, 피부사상균 감염 등 진균 감염의 빈도가 증가하는 추세입니다. 예를 들어, Global Action for Fungal Infections에서 발표한 논문에 따르면, 매년 8,000만 명 이상의 사람들이 곰팡이병으로 사망하거나 시력을 잃을 위험이 높다고 합니다. 매년 약 600만 명의 환자가 생명을 위협하는 진균 감염으로 인해 약 375만 명이 사망하고 있습니다. 이러한 사례 증가로 인해 이러한 감염증을 효과적으로 관리하고 치료하기 위한 항진균제 치료에 대한 수요가 증가하고 있습니다.

만성질환의 출현

당뇨병, 암 등 만성질환을 앓고 있는 사람이 증가하면서 곰팡이 감염의 위험성이 높아지고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면, 2022년 새로 암 진단을 받은 사람은 약 2,000만 명, 사망한 사람은 970만 명에 달할 전망입니다. 평생 약 5명 중 1명이 암에 걸리고, 남성 9명 중 1명, 여성 12명 중 1명이 암으로 사망합니다. 마찬가지로 미국암협회가 발표한 논문에 따르면, 2024년에는 미국에서 약 200만 1,000명의 암 환자가 새로 발생하고, 약 61만 1,700명이 암으로 사망할 것으로 예상했습니다. 암 치료 중이거나 만성질환을 앓고 있는 환자들은 면역력이 저하된 경우가 많아 감염에 취약합니다. 이러한 요인들은 항진균제 시장 예측에 더욱 긍정적인 영향을 미칠 것입니다.

기술 발전

신속 분자 검사, 영상 진단 기술의 향상 등 진단 도구의 발전으로 진균 감염을 보다 빠르고 정확하게 진단할 수 있게 되었습니다. 이는 항진균 치료 증가로 이어집니다. 예를 들어, 2024년 2월 IIT-Bombay에 기반을 둔 HaystackAnalytics와 Neyyattinkara에 위치한 NIMS Medicity는 공동으로 감염병을 식별하기 위한 유전체 검사 'infexnTM'을 발표했습니다. 'infexnTM'은 모든 곰팡이 감염을 검출하도록 설계된 최첨단 표적 차세대 염기서열 분석 검사로 항진균제 시장의 수익을 증대시킬 수 있습니다.

아조르
- 주요 부문
  - Voriconazole (Vfend)
  - Posaconazole (Noxafil)
  - Clotrimazole (Canesten)
  - Isavuconazole (CRESEMBA)
  - 기타
Echinocandins
- 주요 부문
  - Caspofungin (Cancidas)
  - Micafungin (Mycamine/ Funguard)
  - 기타
Polyenes
- 주요 부문
  - Amphotericin (AmBisome)
  - 기타
Allylamines
- 주요 부문
  - Terbinafine (Lamisil)
  - 기타
기타

제7장 시장 분석 : 적응증별

피부 사상균증
아스페르길루스증
칸디다증
- 주요 부문
  - 침습성 칸디다증
  - 칸디다 질염(VVC)
  - 구강/인두/식도 칸디다증
  - 기타
기타

제8장 시장 분석 : 지역별

북미
- 미국
- 캐나다
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
라틴아메리카
- 브라질
- 멕시코
- 기타
중동 및 아프리카

제9장 SWOT 분석

제10장 밸류체인 분석

제11장 Porter의 Five Forces 분석

제12장 가격 분석

제13장 경쟁 구도

시장 구조
주요 기업
주요 기업 개요
- Abbott Laboratories
- Arcadia Consumer Healthcare Inc.
- Astellas Pharma Inc.
- Bayer AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Scynexis Inc.

LSH

영문 목차

영문목차

The global antifungal drugs market size reached USD 15.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 20.6 Billion by 2033, exhibiting a growth rate (CAGR) of 2.99% during 2025-2033. The rising prevalence of fungal infections, ongoing advancement in antifungal drug development, improved diagnostic technologies, and expanding geriatric population, are primarily driving the market's growth.

Antifungal Drugs Market Trends:

Rising Prevalence of Fungal Infections

The frequency of fungal infections, such as candidiasis, aspergillosis, and dermatophyte infections, is on the rise. For instance, according to an article published by Global Action for Fungal Infections, each year, more than 80 million individuals are at high risk of dying from a fungal disease or losing their vision. Every year, approximately 6 million patients contract life-threatening fungal infections, with nearly 3.75 million dying as a result. This increase in cases drives higher demand for antifungal treatments to manage and treat these infections effectively.

Emergence of Chronic Diseases

The increasing number of individuals with chronic conditions, such as diabetes and cancer, heightens the risk of fungal infections. For instance, according to the World Health Organization (WHO), in 2022, there were nearly 20 million new cancer diagnoses and 9.7 million fatalities. About 1 in 5 people develop cancer in their lifetime, and about 1 in 9 men and 1 in 12 women die from it. Similarly, according to an article published by the American Cancer Society, in 2024, nearly 2,001,000 new cancer cases and approximately 611,700 cancer deaths were expected in the United States. Patients undergoing cancer treatments or those with chronic illnesses often have weakened immune systems, making them more susceptible to infections. These factors further positively influence the antifungal drugs market forecast.

Technological Advancements

Advances in diagnostic tools, such as rapid molecular tests and improved imaging techniques, enable earlier and more accurate diagnosis of fungal infections. This leads to increased use of antifungal treatments. For instance, in February 2024, HaystackAnalytics, based at IIT-Bombay, and NIMS Medicity, located in Neyyattinkara, collaborated to introduce 'infexnTM', a genomics test for identifying infectious disorders. The 'infexnTM' is a cutting-edge targeted next-generation sequencing test designed to detect any fungal infection, thereby boosting the antifungal drugs market revenue.

Global Antifungal Drugs Industry Segmentation:

Breakup by Drug Class:

Azoles
- Voriconazole (Vfend)
- Posaconazole (Noxafil)
- Clotrimazole (Canesten)
- Isavuconazole (CRESEMBA)
- Others
Echinocandins
- Caspofungin (Cancidas)
- Micafungin (Mycamine/ Funguard)
- Others
Polyenes
- Amphotericin (AmBisome)
- Others
Allylamines
- Terbinafine (Lamisil)
- Others
Others

Azoles currently hold the largest market share

According to the antifungal drugs market outlook, azoles are effective against a broad spectrum of fungi, including Candida species, Aspergillus species, and dermatophytes. This broad activity makes them suitable for treating a wide range of fungal infections. Moreover, the emergence of drug-resistant fungal strains, such as resistant Candida and Aspergillus species, has created a need for effective antifungal treatments. New azoles and those with improved pharmacological profiles are being developed to address these resistance issues. Azoles are often used in combination with other antifungal agents to enhance efficacy against resistant strains and reduce the risk of resistance development.

Breakup by Indication:

Dermatophytosis
Aspergillosis
Candidiasis
- Invasive Candidiasis
- Vulvovaginal Candidiasis (VVC)
- Mouth/Throat/Esophageal Candidiasis
- Others
Others

Currently, candidiasis exhibits a clear dominance in the market

According to the antifungal drugs market overview, candidiasis is one of the most common fungal infections, particularly in immunocompromised patients, including those with HIV/AIDS, cancer, diabetes, or undergoing organ transplants. The high prevalence of this infection drives demand for effective antifungal treatments. Moreover, candidiasis is also a common healthcare-associated infection, particularly in hospitalized patients with central venous catheters or those undergoing invasive procedures. This drives the need for potent antifungal therapies in hospital settings.

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.

According to the antifungal drugs market statistics, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. For instance, according to an article published by the U.S. Centers for Disease Control and Prevention, an estimated 25,000 cases of candidemia occur in the United States each year. This rise in infection rates drives demand for effective antifungal treatments. Moreover, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. This rise in infection rates drives demand for effective antifungal treatments. Furthermore, innovations in antifungal drug development, including the introduction of new classes of antifungals such as newer azoles and echinocandins, enhance treatment options and drive market growth.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

Abbott Laboratories
Arcadia Consumer Healthcare Inc.
Astellas Pharma Inc.
Bayer AG
GlaxoSmithKline Plc
Merck & Co. Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi S.A.
Scynexis Inc.

Key Questions Answered in This Report

1.What was the size of the global antifungal drugs market in 2024?
2.What is the expected growth rate of the global antifungal drugs market during 2025-2033?
3.What has been the impact of COVID-19 on the global antifungal drugs market?
4.What are the key factors driving the global antifungal drugs market?
5.What is the breakup of the global antifungal drugs market based on the drug class?
6.What is the breakup of the global antifungal drugs market based on the indication?
7.What are the key regions in the global antifungal drugs market?
8.Who are the key players/companies in the global antifungal drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Antifungal Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class

6.1 Azoles
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Voriconazole (Vfend)
  - 6.1.2.2 Posaconazole (Noxafil)
  - 6.1.2.3 Clotrimazole (Canesten)
  - 6.1.2.4 Isavuconazole (CRESEMBA)
  - 6.1.2.5 Others
- 6.1.3 Market Forecast
6.2 Echinocandins
- 6.2.1 Market Trends
- 6.2.2 Key Segments
  - 6.2.2.1 Caspofungin (Cancidas)
  - 6.2.2.2 Micafungin (Mycamine/ Funguard)
  - 6.2.2.3 Others
- 6.2.3 Market Forecast
6.3 Polyenes
- 6.3.1 Market Trends
- 6.3.2 Key Segments
  - 6.3.2.1 Amphotericin (AmBisome)
  - 6.3.2.2 Others
- 6.3.3 Market Forecast
6.4 Allylamines
- 6.4.1 Market Trends
- 6.4.2 Key Segments
  - 6.4.2.1 Terbinafine (Lamisil)
  - 6.4.2.2 Others
- 6.4.3 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Indication

7.1 Dermatophytosis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Aspergillosis
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Candidiasis
- 7.3.1 Market Trends
- 7.3.2 Key Segments
  - 7.3.2.1 Invasive Candidiasis
  - 7.3.2.2 Vulvovaginal Candidiasis (VVC)
  - 7.3.2.3 Mouth/Throat/Esophageal Candidiasis
  - 7.3.2.4 Others
- 7.3.3 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 United States
  - 8.1.1.1 Market Trends
  - 8.1.1.2 Market Forecast
- 8.1.2 Canada
  - 8.1.2.1 Market Trends
  - 8.1.2.2 Market Forecast
8.2 Asia-Pacific
- 8.2.1 China
  - 8.2.1.1 Market Trends
  - 8.2.1.2 Market Forecast
- 8.2.2 Japan
  - 8.2.2.1 Market Trends
  - 8.2.2.2 Market Forecast
- 8.2.3 India
  - 8.2.3.1 Market Trends
  - 8.2.3.2 Market Forecast
- 8.2.4 South Korea
  - 8.2.4.1 Market Trends
  - 8.2.4.2 Market Forecast
- 8.2.5 Australia
  - 8.2.5.1 Market Trends
  - 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
  - 8.2.6.1 Market Trends
  - 8.2.6.2 Market Forecast
- 8.2.7 Others
  - 8.2.7.1 Market Trends
  - 8.2.7.2 Market Forecast
8.3 Europe
- 8.3.1 Germany
  - 8.3.1.1 Market Trends
  - 8.3.1.2 Market Forecast
- 8.3.2 France
  - 8.3.2.1 Market Trends
  - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
  - 8.3.3.1 Market Trends
  - 8.3.3.2 Market Forecast
- 8.3.4 Italy
  - 8.3.4.1 Market Trends
  - 8.3.4.2 Market Forecast
- 8.3.5 Spain
  - 8.3.5.1 Market Trends
  - 8.3.5.2 Market Forecast
- 8.3.6 Russia
  - 8.3.6.1 Market Trends
  - 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
8.4 Latin America
- 8.4.1 Brazil
  - 8.4.1.1 Market Trends
  - 8.4.1.2 Market Forecast
- 8.4.2 Mexico
  - 8.4.2.1 Market Trends
  - 8.4.2.2 Market Forecast
- 8.4.3 Others
  - 8.4.3.1 Market Trends
  - 8.4.3.2 Market Forecast
8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 Arcadia Consumer Healthcare Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
- 13.3.3 Astellas Pharma Inc.
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
- 13.3.4 Bayer AG
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
  - 13.3.4.4 SWOT Analysis
- 13.3.5 GlaxoSmithKline Plc
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 Financials
- 13.3.6 Merck & Co. Inc.
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 Merck KGaA
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 Novartis AG
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
  - 13.3.8.4 SWOT Analysis
- 13.3.9 Pfizer Inc.
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
  - 13.3.9.3 Financials
  - 13.3.9.4 SWOT Analysis
- 13.3.10 Sanofi S.A.
  - 13.3.10.1 Company Overview
  - 13.3.10.2 Product Portfolio
  - 13.3.10.3 Financials
  - 13.3.10.4 SWOT Analysis
- 13.3.11 Scynexis Inc.
  - 13.3.11.1 Company Overview
  - 13.3.11.2 Product Portfolio
  - 13.3.11.3 Financials